News

WHO Releases Global Tuberculosis Report 2012

Click here to read full report.

The WHO released the Global Tuberculosis Report 2012 today. The main take home points are:

  • In the space of 17 years, 51m people were successfully treated for TB saving 20m lives.
  • TB rates worldwide are decreasing but the overall burden remains huge with drug-resistance becoming more and more of a challenge. Asia is the hardest hit region with the largest numbers of TB cases with the majority in China and India. Africa and Europe are not seeing rates decline as quickly as other regions.
  • The new statistics highlight the urgent need for new tools, such as new drugs, new diagnostics, and new vaccines ,to significantly impact the burden of TB and reach the goals outlined in the Global Plan to Stop TB.
  • Funding for tuberculosis research and implementation needs to increase to address this disease that is still killing over a million people a year. Current funding levels are just inadequate.

Additional Coverage:

In new report, WHO warns global fight against TB now at a crossroads

TB rates down, but its ‘global burden’ remains huge, WHO reports

World TB cases fall, but drug-resistance a worry: WHO

Tuberculosis effort in real danger – WHO

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...